Spectral Diagnostics, Toray Medical join forces to tackle sepsis:
This article was originally published in Clinica
Canadian diagnostics developer Spectral Diagnostics and Toray Medical, a subsidiary of Japan's diversified chemicals group Toray, have formed what they claim to be the first "theranostic" alliance to improve management of severe sepsis. Under the agreement, the two companies will co-promote the use of Spectral's Endotoxin Activity Assay (EAA) for measuring levels of blood-borne endotoxin, together with Toray's Toraymyxin blood purification device for removing the noxious agent. Endotoxin is the most common mediator of sepsis and enables doctors to assess a patient's risk of developing the severe form of the condition.
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.